BCTX - BriaCell Harvard enter research agreement to identify targets for cancer treatments
- BriaCell Therapeutics ( NASDAQ: BCTX ) on Wednesday announced a research collaboration agreement with Harvard Medical School to discover new targets for the development of anti-cancer treatments.
- The year-long collaboration will focus on the discovery and development of targets to improve the response of tumor cells to chemotherapy and immunotherapies in specific cancers such as lung, head, neck, cervical and bladder.
- BCTX said it would have the option to negotiate a license for the targets that come up under the collaboration.
- The project at Harvard Medical School will be led by faculty member Joan Brugge.
- BCTX stock opened slightly higher at $6.28.
For further details see:
BriaCell, Harvard enter research agreement to identify targets for cancer treatments